CONFIRM trial publishes trial protocol in open access journal

Published: 20 April 2018

CCI building — Centre for Cancer Immunology building

Patients with a hard-to-treat type of cancer are being given new hope in a new clinical trial. Researchers at the University of Southampton and the University of Leicester are trialling a drug that could boost the body’s immune system to fight off mesothelioma, which can be caused by asbestos. The trial will be one of many to be conducted at the University of Southampton’s Centre for Cancer Immunology, which will be the UK’s first and only centre dedicated to cancer immunology research.

The trial protocol has been published in an open access journal

CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial

Authors

Dean A. Fennell,
Emma Kirkpatrick,
Kelly Cozens,
Mavis Nye,
Jason Lester,
Gerard Hanna,
Nicola Steele,
Peter Szlosarek,
Sarah Danson,
Joanne Lord,
Christian Ottensmeier,
Daniel Barnes,
Stephanie Hill,
Mihalis Kalevras,
Tom Maishman and
Gareth Griffiths

Citation

Trials201819:233
https://doi.org/10.1186/s13063-018-2602-y

Articles that may also interest you

New trial tests whether a targeted drug can help patients with a hard-to-treat cancer

“I’ve seen the effects of cancer, both personally and through my work” – Senior Trial Manager Josh runs the London Marathon to raise funds for CRUK

Easter closure notice 2024

Share this article Share this on Facebook Share this on Twitter Share this on Weibo